Boehringer Ingelheim has reported data from a new sub-analysis of the RE-LY clinical trial that further underlines the benefits of its anticoagulant product Pradaxa.
Results published in the European Journal of Heart Failure showed that Pradaxa can offer advantages over warfarin among difficult-to-treat patients with non-valvular atrial fibrillation and previous symptomatic heart failure.
“Boehringer Ingelheim has announced new trial data for Pradaxa showing the benefits it provides for difficult-to-treat patients with atrial fibrillation and symptomatic heart failure.“
A 150mg dose of the drug was able to reduce the risk of stroke with similar rates of major bleeding compared to warfarin, while the 110mg dose showed similar rates of stroke but significantly reduced major bleeding.
This further reinforces the consistent efficacy and safety profile of Pradaxa that has been shown in the main RE-LY trial and various previous sub-analyses.
Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "These new results from RE-LY highlight the value of Pradaxa also for those atrial fibrillation patients that are traditionally considered difficult to treat and have multiple comorbidities."
Last month, the company applied for European approval of Pradaxa as a treatment for acute deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of recurrent DVT and PE.See all the latest jobs in Pharmaceutical